〔Abstract〕 Objective To investigate the effects of quetiapine fumarate tablets combined with lithium carbonate on inflammatory response and cognitive function in patients with bipolar disorder (BD). Methods A total of 68 BD patients with manic episodes admitted to the Eighth People's Hospital of Zhengzhou from June 2020 to June 2022 were selected as the study objects, and were divided into the control group (given lithium carbonate treatment) and the observation group (given quetiapine fumarate tablets combined with lithium carbonate treatment) according to random number table method, with 34 cases in each group. After continuous treatment for 1 month, patients in both groups were treated. The inflammatory response indexes, cognitive function indexes and adverse reactions were compared before and after treatment. Results After treatment, the serum levels of hypersensitive C-reactive protein (hs-CRP), tumor necrosis faction-α (TNF-α), absolute values of peripheral blood lymphocytes and neutrophils in the observation group were lower than those in the control group, and the cognitive function impairment was less than that in control group, with statistical significance (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion Quetiapine fumarate tablets combined with lithium carbonate can reduce inflammation and improve cognitive function in BD patients with manic episodes without increasing adverse reactions.